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Academic and public interest in tDCS has been fueled by strong claims of therapeutic and enhancement
effects. We report a rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical
issues need to be addressed.Introduction
Neurostimulation has a long history of
attracting academic and public attention.
The Egyptians knew about the electric
properties of catfish (Finger, 1994), but it
is unclear if (and how) they experimented
with them for clinical purposes. Both Plato
and Aristotle described the ability of the
torpedo fish to generate numbing effects
via its electric discharge (Finger, 1994).
Later writings from Scribonius Largus,
Pliny the Elder, and Galen of Pergamum
detail the use of live torpedo fish to treat
headaches (Priori, 2003). The Romans
went beyond scholarly interest by culti-
vating the fish for explicit therapeutic
purposes, as evidenced by a frescoed
store front that marketed their use to the
public in Pompeii (Finger, 1994). Other
therapeutic uses of brain stimulation
were reported by Ibn-Sidah, an 11th cen-
tury physician, who suggested using an
electric catfish to treat epilepsy (Brunoni
et al., 2012). With the advent of electro-
physiology in the 1700s, direct current
began to be used in clinical settings for
the treatment of melancholia (Priori,
2003). These advances drew significant
public interest and generated discussion
about their philosophical and ethical im-
plications (e.g., Shelley’s Frankenstein).
Principles of Neurostimulation
Early interventions involving electrical
stimulation of the brain used direct current
(DC) (as opposed to alternating current
[AC] or magnetic fields, which were both
introduced toward the end of 19th cen-tury). Ancient therapeutic practices as
bizarre as applying a live torpedo fish to
the scalp to cure headaches could thus
qualify as a crude form of transcranial
direct current stimulation (tDCS): they
were transcranial (as opposed to intra-
cranial), they used DC, and the desired
effect was brain stimulation. Modern-day
tDCS devices use weak electrical current
(0.5–2 mA, such as that provided by a
9 V battery) and at least two electrodes
placed on the scalp to facilitate or inhibit
spontaneous neuronal activity. Although
this effect is poorly understood, it is theo-
rized that tDCS may induce long-term
potentiation (LTP), a process thought to
contribute to learning (Stagg and Nitsche,
2011). The effects of tDCS seem to be
most pronounced when combined with a
training paradigm (Hamilton et al., 2011).
It is known that tDCS acts by polariz-
ing the resting membrane potential, the
effects of which can last for up to 1 hr
(Priori, 2003). Given that tDCS causes a
constant electric field that displaces all
electrically charged molecules and that
most neurotransmitters and receptors
in the brain have electrical properties,
tDCS might induce prolonged neuro-
chemical changes that are as of yet
unknown (see Brunoni et al., 2012). The
mechanisms of action of tDCS could
involve different synaptic and nonsynap-
tic effects on neurons, nonneuronal cells
(e.g., glia), and tissues within the brain
(Brunoni et al., 2012). The long-lasting
effects of tDCS may also depend on pro-
tein synthesis, since anodal stimulationNeuronappears to increase intraneuronal levels
of calcium as well as the expression of
genes responsible for neurotransmitter
receptors (see Stagg and Nitsche, 2011).
Neurostimulation in theModernAge
In modern times, the persistent challenge
of treating complex conditions such as
epilepsy, chronic pain, and headaches
has served as a catalyst for the develop-
ment of neurostimulation techniques.
The success of electroconvulsive therapy
(ECT) as a treatment for psychiatric disor-
ders in the mid-1900s largely pushed
techniques using weak electric current
out of popular use for several decades
(Priori, 2003). However, the public’s
strongly negative opinion of ECT contrib-
uted to the desertion of this technique
despite its therapeutic efficacy in the
treatment of depression (Lauber et al.,
2005). Investigations into weak direct
currents returned briefly in the 1960s but
were once again abandoned with the
rising use of psychopharmaceuticals to
treat mental illness (Priori, 2003).
Over the past several decades, neuro-
stimulation techniques have gradually
gained favor in the public eye. A surge
of interest in invasive (e.g., deep brain
stimulation [DBS]) and noninvasive forms
of neurostimulation (e.g., transcranial
magnetic stimulation [TMS] and trans-
cranial direct current stimulation [tDCS])
has propelled research that examines
the therapeutic potential of these tech-
niques. Currently, tDCS is primarily used
as an investigative and therapeutic tool82, May 21, 2014 ª2014 Elsevier Inc. 731
Figure 1. The Increasing Number of Articles on tDCS and Applications Described
The data for 2013 reflect articles published from January 1st to October 1st.
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NeuroViewin the context of pain, neurorehabilita-
tion after stroke, and depression (Stagg
and Nitsche, 2011). However, tDCS has
garnered considerable attention due to
its capacity to enhance neurological func-
tion (Hamilton et al., 2011). Recently, the
technique has caused excitement in the
lay public and academia as a ‘‘portable,
painless, inexpensive and safe’’ thera-
peutic and enhancement device (Cohen
Kadosh et al., 2012). Yet, despite these
claims, the safety and efficacy of tDCS
have only been demonstrated in con-
trolled laboratory settings and, without
supervision, the use of tDCS for enhance-732 Neuron 82, May 21, 2014 ª2014 Elsevierment might cause serious adverse effects
such as temporary respiratory paralysis
(Brunoni et al., 2012). Thus, the effects
of tDCS are hard to predict.
Media coverage of stimulation tech-
niques is now often enthusiastic about
the benefits these techniques could yield.
For example, media discussions about
DBS have been optimistic, with little
explicit discussion concerning ethical
issues, therapeutic limitations, or side
effects that could result from the wide-
spread use of DBS (Racine et al., 2007).
Given the nature of tDCS and the lack of
oversight governing its use, academicInc.and print media discourse could shape
the public’s risk-benefit perceptions,
impact the uptake of this technology,
and, consequently, lead to negative
implications for ethical and regulatory
oversight. Indeed, such positive por-
trayals in the media have been shown to
indirectly affect patient understanding
and consent for DBS (Bell et al., 2010).
Portrayal of tDCS in the Media
To better assess publically available infor-
mation and discussions about tDCS,
we analyzed academic and print media
coverage of this technique.We performed
academic literature searches on PubMed
using the keywords ‘‘transcranial direct
current stimulation’’ OR ‘‘transcranial
electrical stimulation’’ OR ‘‘direct current
brain polarization’’ and established the
relevance of academic papers by ana-
lyzing the abstracts. Exclusion criteria
included papers without an abstract in
English or available full text, detailing
techniques other than tDCS, reporting
the use of tDCS during surgery or under
anesthesia, and unpublished proofs (re-
sults: 1,237 retrieved articles; 948 rele-
vant papers). One additional relevant
paper that was repeatedly referred to in
the literature but not captured in our
searches was also included.
We used a similar strategy to search
the Factiva database for relevant print
media articles (306 retrieved articles; 218
relevant articles). The print media analysis
included English language articles that
provide information about tDCS to the
general public. Exclusion criteria included
sources targeting medical professionals,
irrelevant article types (e.g., obituaries),
and duplicates. Additionally, 18 online-
only articles were excluded.
Articles were coded systematically
by two independent coders. The coding
structure included the identification of (1)
the year of publication, (2) type of source
(print media or academic), (3) type of
tDCS application described (therapeutic,
enhancement, technical, or investigative),
and (4) overall tone (optimistic, critical,
or neutral/balanced). For both academic
and print media literature, therapeutic
applications referred to the use of
tDCS within a patient population to
improve their condition, while technical
descriptions referred to general infor-
mation about the technique. Both the
Table 1. Illustrative Examples of Headlines in Print Media Reports on Therapeutic and Enhancement Use of tDCS
Therapeutic Application Enhancement Application
‘‘Mild jolt for beating blues’’ (Hobart Mercury, February 16, 2006) ‘‘Electrify your mind’’ (New Scientist, April 15, 2006)
‘‘Psychiatry’s shocking new tools’’ (IEEE Spectrum, March 1, 2006) ‘‘Little brain zap, big memory boost’’ (New Scientist, August 2010)
‘‘Brain stimulation improves memory in Alzheimer’s’’ (Reuters News,
August 22, 2008)
‘‘A tiny zap to improve memory’’ (The Philadelphia Inquirer,
October 23, 2010)
‘‘Therapies replace electroshock’’ (Montreal Gazette,
October 9, 2010)
‘‘Zapping brain boosts math skills’’ (Investor’s Business Daily,
November 8, 2010)
‘‘Tiny brain shocks may help schizophrenia patients’’
(The Conversation, July 28, 2011)
‘‘Got a problem – put your electrical thinking cap on’’
(Guardian Unlimited, February 2, 2011)
‘‘Electricity zap to brain aids stroke recovery’’
(Daily Mail, September 16, 2011)
‘‘A zap to brain to bring out the genius in you’’
(The Press Trust of India, February 3, 2011)
‘‘Getting a head start’’ (The Engineer, January 23, 2012) ‘‘Electric shock improves academic performance’’
(Indo-Asian News Service, January 26, 2012)
‘‘Brainwave is a breakthrough’’ (St George & Sutherland Shire Leader,
March 6, 2012)
‘‘Zen and the art of genius’’ (New Scientist, February 4, 2012)
‘‘Electric zap stops migraines’’ (Investor’s Business Daily, May 2, 2012) ‘‘Jump-start your brain’’ (Boston Magazine, June 1, 2012)
‘‘Zap your way out of depression’’ (Timaru Herald, February 14, 2013) ‘‘Spark of Genius’’ (Sunday Tribune, April 7, 2013)
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tions detailed the use of tDCS in healthy
populations; enhancement reflects tDCS
used specifically to improve some aspect
of performance, while investigative refers
to all other types of tDCS studies (e.g.,
on moral judgment).
TheRising Tide of tDCS in theMedia
and Academic Literature
The amount of information on tDCS
available to the public has increased
dramatically in recent years in both aca-
demic literature and print media articles
(Figure 1).
Even though modern uses of tDCS
have been reported in peer-reviewed
academic literature since 1964, the
earliest print media article on this topic
we found was published in 2006. This
publication date coincides with a sub-
stantial increase in volume of academic
literature on tDCS and the appearance
of several academic papers reporting
the therapeutic and enhancement effects
of tDCS.
There was a considerable mismatch
between the focus in academic and print
media articles. The academic articles
focused primarily on therapeutic uses of
tDCS (n = 428; 45%), followed by investi-
gative uses (n = 297; 31%). Enhancement
use was the dominant topic in only 120
articles (13%) and was followed closely
in number by technical aspects (n = 104;
11%). In print media articles, discussions
surrounding potential enhancement usesof tDCS were the primary focus of 92
(42%), with an equal number (n = 92; 42%)
focusing on therapeutic applications of
tDCS. These were followed by descrip-
tions of investigative uses (n = 23; 11%)
and technical aspects (n = 11; 5%).
The majority of print media headlines
were enthusiastic and described tDCS
as an ‘‘amazing new technique’’ and
only highlighted the potential benefits of
tDCS (Table 1). We encountered strong
and potentially misleading statements
about the real-world effects and applica-
bility of tDCS (e.g., ‘‘schoolchildren who
struggle to grasp mathematics could
benefit from having their brains roused
with electricity’’ [The Guardian, April 11,
2010]). In the entire sample of relevant
articles, only eight (3.5%) advised caution
or mentioned the possibility of adverse
effects (Figure 2). The fact that the mech-
anisms of action of tDCS are unknown
and that long-term changes could also
include adverse effects were almost
never mentioned.
Academic articles, while also enthusi-
astic, usually involved more balanced
discussions. The academic literature
also mentioned safety issues, the need
for technical improvements, and potential
adverse effects from the use of tDCS
more frequently than in the print media,
where these conversations were largely
lacking.
Print media articles sensationalized the
capabilities of tDCS (e.g., ‘‘tDCS. could
improve anything from focus and motorNeuroncontrol to moral reasoning. It’s simple.
It’s relatively cheap’’ [Sunday Tribune,
July 4, 2013]). In the print media, findings
about tDCS were also combined with
misconceptions (e.g., ‘‘It is a known fact
that humans only use 10% of their brain.
. with the advancements in technology
a person can boost this capacity. By
attaching a 9 V battery to the scalp.’’
[TopNews, October 3, 2013]). Therefore,
not only was the content reported by the
two media types different, but the way in
which they reported the information was
as well.
Implications of the Rising Tide
of tDCS and the Way Forward
Given the rapid evolution of tDCS in the
public domain and in academia, tackling
its social, ethical, and policy implications
requires a multifaceted response. We
explore three areas of action.
Increasing Neuroscientific Literacy
The enthusiastic depiction of neuroscien-
tific and neurotechnological advances
can generate deep publicmisunderstand-
ings about the scientific and clinical
aspects of these findings (e.g., Racine
et al., 2007, 2010). By not measuring
(and hence not reporting) the potential
detrimental effects of tDCS, experiments
reported in academic papers could also
bolster the perception that tDCS induces
cognitive enhancement. However, it is un-
clear if such an effect provokes collateral
inhibition of other cognitive functions
(Iuculano and Cohen Kadosh, 2013). The82, May 21, 2014 ª2014 Elsevier Inc. 733
Figure 2. Areas of Application and Tone of tDCS Print Media Articles
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acting behind tDCS is a simple and
accessible concept to the layperson, in
addition to the long-standing history of
using noninvasive current in therapeutic
contexts, may increase the public’s
enthusiasm for and comfort in using this
device for enhancement. This, in turn,
could lead to a swell in public interest
and to the broad use of the technique.
To curtail misunderstandings about
tDCS, professional societies and re-
searchers, perhaps in collaboration with
academic publishers, could help the pub-
lic understand the mechanisms, limita-734 Neuron 82, May 21, 2014 ª2014 Elseviertions, and genuine therapeutic potential
of tDCS. Governmental agencies, such
as the NIH, could issue health warnings
about tDCS to increase the public’s
scientific literacy. This information could
clarify the mechanism of action of tDCS
and potential safety concerns in layman’s
terms as well as clearly outline the current
state of research. Beyond its usefulness
for the public, clinicians, and others, this
information would serve as a reference
to media outlets wishing to discuss
tDCS knowledgeably. Additionally, re-
searchers, journalists, and other mem-
bers of the media who frequently writeInc.about scientific topics could receive
training concerning how to translate
neuroscientific information to the public.
Monitoring and Regulating tDCS
Devices
The wide availability of tDCS is a signifi-
cant issue (Fitz and Reiner, 2013; Bikson
et al., 2013; Maslen et al., 2014). While
some companies have imposed self-
restraint on the sale of this technology
(Table 2), such self-regulation does not
resolve the issue. Even if tDCS devices
as products were only sold to physicians,
a secondary market for tDCS as a thera-
peutic and enhancement service seems
to be on the rise, making the issue of
training requirements salient. The most
concerning aspect is the virtually omni-
present availability of tDCS as a simple
do-it-yourself gadget: several websites
offer detailed instructions on how to build
a tDCS device and where to place elec-
trodes to achieve enhancement (Table 2).
The regulation of medical devices is
a complex area where discrepancies
between European, North American, and
Asian markets create significant chal-
lenges by impacting the dissemination
and use of these devices internationally.
Currently, the regulatory regimes have
important blind spots: devices may be
designated as ‘‘safe’’ without any review
of claims about their effectiveness.
Furthermore, manipulating claims about
effectiveness might lead to admission of
devices by regulatory default (Guleyupo-
glu et al., 2013). The European Union
‘‘CE’’ (i.e., conformite´ europe´enne) mark
can be obtained by mere compliance
with production standards as long as
no medical claims are made in the
application. In the U.S., medical claims
regarding a device that is ‘‘substantially
equivalent’’ to a formerly ‘‘cleared’’ device
allow this similar device to be marketed
(FDA, 2014). Therefore, producers that
claim that tDCS has medical uses are
able to do so because similar devices
that generate weak electrical currents
have been used effectively for rehabilita-
tion of muscle injuries.
Postmarket surveillance is another
crucial aspect that falters in its current
shape and form even for invasive
implantable devices (e.g., DBS). There is
currently no consensus on tDCS regu-
lation, though several leading authors
have proposed ways to manage devices
Table 2. Examples of the International Availability of tDCS
Country Webpage Advertised Application Targeted Market Disclaimer/Restrictions in Access
tDCS as a Product
Germany http://www.neuroconn.de/dc-stimulator_mc_en/ Investigative Researchers No training required
Hong Kong http://www.trans-cranial.com/ Therapy, enhancement Unspecified individual users No training required;
world-wide shipping
United States http://tdcsdevicekit.com/index.php/wholesale-distributors Therapy, enhancement Wholesale distributors,
unspecified individual users
No training required
Canada http://www.mindalive.com/Products_OASIS_Pro.htm Therapy, enhancement Physicians Physicians only
United Kingdom
and United States
http://www.foc.us/ Enhancement (neurogaming) Unspecified individual users No training required;
‘‘The foc.us [device].
is not a medical device,
and is not regulated by
the FDA;’’ ‘‘The headset
is not a toy, is not
recommended for under
18s, epilepsy sufferers
or people with implants.’’
tDCS as a Service
United States http://www.transcranialbrainstimulation.com/ Therapy Psychiatric and
neurological conditions
No disclaimers or restrictions
United Kingdom http://www.york-biofeedback.co.uk/neurofeedback/tdcs.aspx Therapy, enhancement Decrease in symptoms,
increase in cognition
Not used on minors
Canada http://www.drmueller-healthpsychology.com/tDCS.html Therapy Depression and chronic pain No disclaimers or restrictions
tDCS as a Do-It-Yourself Device
Presentation Form
– http://speakwisdom.wordpress.com/2012/12/09/
can-a-simple-safe-tdcs-device-be-built-from-radio-
shack-components/
Therapy, enhancement,
investigative ‘‘tDCS.
Swiss Army knife of
21st Century’’
Step-by-step tutorial
– http://www.youtube.com/watch?v=hgFWEBwT6BE Therapy, enhancement,
investigative
Step-by-step tutorial
– http://www.youtube.com/watch?v=h1Y3cpB26IY Therapy, enhancement,
investigative
Commercial presentation quoting scientific studies
Note: the list found in this table is representative, not exhaustive. All webpages accessed on March 7, 2014.
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NeuroViewwith enhancement effects by accommo-
dating them within the current regulations
for medical devices (Maslen et al., 2014).
Most proposals posit that solutions
should include the monitoring of adverse
events stemming from tDCS in addition
to paying closer attention to marketing
and manufacturing standards. Simple
policy actions could be to make manda-
tory disclaimers about the current evi-
dence supporting tDCS. Training and
licensing procedures should also be
considered (Dubljevic, 2012).
Supporting Responsive and Ethical
Clinical Practice
At this time, raising clinicians’ awareness
about tDCS as an emerging and largely
unregulated device is warranted. Previous
clinical responses to other forms of un-
proven therapies are pillars to build from.
In such cases, clinicians must balance
the potential benefits of the device with
their unknown risks, as well as other impli-
cations for users such as the exclusion
from prospective clinical trials, financial
costs, and clinical follow-up. Clarifying
the role of clinicians with respect to en-
hancement uses of tDCS brings another
level of complexity given that such uses
raise distinct ethical and social issues
that are not well covered by current clin-
ical practice guidelines. The American
Academy of Neurology has proposed
that physicians have leeway in accept-
ing or declining requests for cognitive
enhancement drugs based on their exper-
tise (Larriviere et al., 2009). Although it is
encouraging to see a professional society
address this issue, this proposal neither
provides clear guidance to physicians
about what they should do nor is it directly736 Neuron 82, May 21, 2014 ª2014 Elsevierapplicable to the distinct issues raised by
cognitive enhancement devices.
The use of tDCS in pediatric popula-
tions also amplifies the ethical challenges
of crafting responsible clinical practice
due to the uncertainty of its long-term
effects on developing brains. This could
call for more protective approaches (as
suggested in the context of pediatric use
of enhancement drugs, see Graf et al.,
2013). Physicians and other clinicians
have—up until now—not been actively
engaged in tackling ethical, clinical, and
policy aspects of tDCS. However, their
crucial role in the public eye as knowl-
edgeable and informed advisors for
medical decision making calls for their
involvement in the clinical aspects of
policy responses to tDCS.
In conclusion, the media have enthusi-
astically reported that tDCS could be
used to enhance cognitive function. The
current regulatory gap means that tDCS
is readily available as a service, product,
or even a homemade device, in many
countries without any guidance being
provided by policy makers. A response
to the policy and regulatory aspects of
tDCS is urgently needed.REFERENCES
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